The trajectory of Viagra presents a interesting case for stakeholders in the pharmaceutical sector. While initially a blockbuster success, generating billions, the exclusivity end and the subsequent arrival of off-brand competitors have significantly changed revenue. This presents questions about the long-term sustainability of related therapeutic